Aeterna Zentaris (AEZS +2%) gains today after saying earlier that its oral AKT inhibitor...


Aeterna Zentaris (AEZS +2%) gains today after saying earlier that its oral AKT inhibitor perifosine, when combined with temsirolimus, was well tolerated while treating recurrent or progressive malignant glioma during Phase 1 clinical trials.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs